Court Correct In Dismissing Investor Claims Due To Lack Of Scienter, Panel Rules
BOSTON — A federal district court did not err in dismissing federal securities law claims brought against a biopharmaceutical company and certain of its executive officers for allegedly misrepresenting the likelihood...To view the full article, register now.
Already a subscriber? Click here to view full article